How the Complement System Functions as a Whole
The complement system consists of over 30 proteins that work together like a biological circuit board. When activated, these proteins amplify signals, mark targets for destruction, and recruit immune cells to infection sites. C3 and C5 occupy central positions in this network, acting as molecular decision points that determine whether immune responses proceed or halt. Their strategic locations make them indispensable for proper immune function.
The Classical Pathway: Where C3 Enters the Picture
C3 typically activates through the classical pathway when antibodies bind to pathogens. Once antibodies attach to their targets, they recruit C1 complex, which cleaves C4 and C2. These fragments then combine to form C3 convertase, an enzyme that splits C3 into C3a and C3b. This cleavage represents a crucial amplification step - one C3 convertase molecule can generate over 100 C3 fragments, rapidly escalating the immune response. The system becomes self-perpetuating at this stage.
Alternative and Lectin Pathways: Additional C3 Activation Routes
Beyond the classical pathway, C3 also activates through alternative and lectin routes. The alternative pathway operates continuously at low levels, providing immediate but non-specific defense. Here, spontaneous C3 hydrolysis creates a C3 convertase that amplifies itself on pathogen surfaces. The lectin pathway activates when mannose-binding lectin recognizes carbohydrate patterns on microbes, leading to C3 convertase formation similar to the classical pathway. These parallel routes ensure C3 cleavage occurs regardless of which pathway initiates the response.
C3's Critical Functions: More Than Just a Splitter
C3's importance extends far beyond its cleavage. C3b fragments coat pathogen surfaces through opsonization, marking them for destruction by phagocytes. This tagging system dramatically enhances macrophage and neutrophil efficiency - cells that might ignore unmarked particles immediately recognize C3b-tagged targets. Meanwhile, C3a acts as an anaphylatoxin, triggering mast cell degranulation and increasing vascular permeability. This creates the inflammation necessary for immune cells to reach infection sites.
C3's Role in Immune Complex Clearance
C3 also facilitates the removal of immune complexes from circulation. When antibodies bind antigens, C3b can attach to these complexes, allowing complement receptors on red blood cells and other cells to bind and transport them to the liver and spleen for degradation. Without this clearance mechanism, immune complexes would accumulate in tissues, causing damage. Patients with C3 deficiencies often develop immune complex diseases, demonstrating this function's importance.
Terminal Complement Pathway: C5's Critical Position
C5 becomes relevant only after C3 activation, when C3 convertase cleaves C5 into C5a and C5b. C5a serves as a powerful chemotactic factor, attracting neutrophils, monocytes, and eosinophils to inflammation sites. Its anaphylatoxin activity exceeds even C3a's potency. C5b initiates the terminal pathway by binding C6, then sequentially recruiting C7, C8, and multiple C9 molecules. This assembly forms the membrane attack complex (MAC), which creates pores in pathogen membranes, causing osmotic lysis.
C5's Specialized Functions and Clinical Significance
C5's role in forming the MAC makes it essential for defending against certain pathogens. Neisseria species, including N. meningitidis and N. gonorrhoeae, possess polysaccharide capsules that resist phagocytosis. The MAC provides the only effective elimination mechanism for these bacteria. Patients with C5-C9 deficiencies face dramatically increased risks from these infections, often experiencing recurrent or severe meningococcal disease.
C5a's Chemotactic Properties and Inflammation Amplification
C5a's chemotactic abilities extend beyond simple cell attraction. It upregulates adhesion molecules on endothelial cells, facilitating immune cell extravasation from blood vessels. C5a also activates neutrophils, enhancing their oxidative burst and degranulation capabilities. These effects create a positive feedback loop where inflammation recruits more inflammatory cells, potentially leading to tissue damage if unchecked. This explains why C5a antagonists show promise for treating inflammatory diseases.
Regulatory Mechanisms: Preventing Complement Overactivation
The complement system includes multiple regulatory proteins that prevent damage to host tissues. Factor H and Factor I regulate C3 convertase activity, while CD55 and CD46 protect host cell membranes from C3b deposition. DAF (CD55) accelerates C3 convertase decay, while MCP (CD46) serves as a cofactor for Factor I-mediated C3b cleavage. These regulators ensure complement activation remains confined to pathogen surfaces, protecting healthy tissues from accidental damage.
Clinical Implications: When C3 or C5 Functions Fail
Complement deficiencies produce distinct clinical patterns. C3 deficiency causes recurrent pyogenic infections, particularly from encapsulated bacteria like Streptococcus pneumoniae and Haemophilus influenzae. These patients also develop immune complex diseases and show poor antibody responses to T-dependent antigens. C5-C9 deficiencies specifically increase susceptibility to Neisseria infections while leaving patients relatively protected against other pathogens.
Complement in Autoimmune Diseases
Complement dysfunction contributes to various autoimmune conditions. In systemic lupus erythematosus, immune complex deposition in kidneys and other tissues causes inflammation. Patients with inherited complement deficiencies, particularly C1q, C2, or C4, face dramatically increased lupus risk - some studies suggest 10,000-fold elevations. This occurs because complement normally helps clear apoptotic cells and immune complexes; without it, self-antigens persist and trigger autoimmune responses.
Therapeutic Targeting of C3 and C5
Modern medicine exploits complement knowledge for therapeutic purposes. Eculizumab, a monoclonal antibody targeting C5, prevents MAC formation and treats paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. By blocking C5 cleavage, it prevents red blood cell destruction in these conditions. Similarly, C3 inhibitors like pegcetacoplan address complement-mediated diseases by preventing C3 activation upstream. These therapies demonstrate how understanding C3 and C5 functions enables targeted interventions.
Frequently Asked Questions About C3 and C5
What happens if someone completely lacks C3?
Complete C3 deficiency proves fatal without modern medical intervention. Affected individuals suffer from overwhelming bacterial infections starting in infancy, particularly from encapsulated organisms. They also develop immune complex diseases and show severely impaired antibody responses. Bone marrow transplantation represents the only curative option, though regular prophylactic antibiotics and careful monitoring allow some patients to survive into adulthood.
Can C5 inhibitors treat COVID-19 complications?
Research suggests C5 inhibition might benefit certain COVID-19 patients. The virus can trigger complement overactivation, contributing to the cytokine storm and associated lung damage. By blocking C5 cleavage, inhibitors prevent MAC formation and reduce inflammatory responses. Clinical trials have shown promise, particularly for patients with severe respiratory complications. However, this approach carries infection risks, requiring careful patient selection and monitoring.
How do C3 and C5 relate to age-related macular degeneration?
Age-related macular degeneration involves complement dysregulation in the retina. Genetic variants in complement factor H and other regulators increase disease risk, suggesting local complement activation damages retinal cells. Some studies indicate C3 fragments accumulate in drusen, the characteristic deposits beneath the retina in AMD. While C5 inhibitors haven't proven effective for AMD, understanding complement's role helps explain disease mechanisms and guides therapeutic development.
Are C3 and C5 levels routinely tested in clinical practice?
Routine C3 and C5 testing remains uncommon outside specialized settings. Doctors typically order these tests when suspecting complement deficiencies or monitoring specific conditions like lupus or membranoproliferative glomerulonephritis. Normal C3 levels range from 90-180 mg/dL, while C5 levels usually exceed 30 mg/dL. Low levels suggest consumption through activation or inherited deficiencies. Testing requires specialized laboratories and interpretation by experts familiar with complement disorders.
The Bottom Line on C3 and C5 Functions
C3 and C5 serve as indispensable components of immune defense, functioning as molecular decision points that determine whether immune responses proceed. C3 amplifies signals through its convertases and facilitates pathogen clearance through opsonization and immune complex removal. C5 enables the formation of the membrane attack complex and recruits inflammatory cells through its anaphylatoxin activity. Together, they balance effective pathogen elimination against host tissue protection, with their dysfunction causing distinct clinical syndromes ranging from overwhelming infections to autoimmune diseases. Understanding these proteins' functions continues driving therapeutic innovations that target complement-mediated pathologies.